参考文献/References:
[1] ISHIKAWA M, IWASAKI M, ZHAO Hailin, et al. Sevoflurane and desflurane exposure enhanced cell proliferation and migration in ovarian cancer cells via miR-210 and miR-138 downregulation[J]. International Journal of Molecular Sciences, 2021, 22(4): 1826.
[2] FAHRMANN J F, IRAJIZAD E, KOBAYASHI M, et al. A MYC-Driven plasma polyamine signature for early detection of ovarian cancer[J]. Cancers, 2021, 13(4): 913.
[3] SALWA A, FERRARESI A, CHINTHAKINDI M, et al. BECN1 and BRCA1 deficiency sensitizes ovarian cancer to Platinum therapy and confers better prognosis[J]. Biomedicines, 2021, 9(2): 207.
[4] XU Lijun, ZHENG Qing. Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer[J]. World Journal of Surgical Oncology, 2021, 19(1): 56.
[5] LI Yang, LONG Xiaotao, WANG Ji, et al. miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways[J]. Journal of Orthopaedic Surgery and Research, 2021, 16(1): 71.
[6] LIU Ping, HAN Ziping, MA Qingfeng, et al. Upregulation of microRNA-128 in the peripheral blood of acute ischemic stroke patients is correlated with stroke severity partially through inhibition of neuronal cell cycle reentry[J]. Cell Transplantation, 2019, 28(7): 839-850.
[7] VERNUCCIO F, GODFREY D, MEYER M, et al. Local tumor control and patient outcome using stereotactic body radiation therapy for hepatocellular carcinoma: iRECIST as a potential substitute for traditional criteria[J]. American Journal of Roentgenology, 2019, 213(6): 1232-1239.
[8] ROHR I, ALAVI S, RICHTER R, et al. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ ENGOT-ov22 and GCIG survey (Expression IV)[J]. International Journal of Gynecological Cancer, 2020, 30(4): 509-514.
[9] STEFFEN T, H?LLER L, BIJELIC L, et al. Decision-making analysis for hyperthermic intraperitoneal chemotherapy in ovarian cancer:a survey by the executive committee of the peritoneal surface oncology group international(PSOGI)[J]. Oncology, 2021, 99(1): 41-48.
[10] ECKSTEIN M, SAILER V, NIELSEN B S, et al. Co-staining of microRNAs and their target proteins by miRNA in situ hybridization and immunohistofluorescence on prostate cancer tissue microarrays[J]. Laboratory Investigation, 2019, 99(10): 1527-1534.
[11] PISHKARI S, PARYAN M, HASHEMI M, et al. The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies[J]. Journal of Endocrinological Investigation, 2018, 41(3): 269-283.
[12] 侯娟，蒋树立，滕长财．基于 TCGA数据库卵巢癌患者的 miR-301b表达量与生存状况生物信息学分析 [J].现代检验医学杂志，2020，35(4): 37-40. HOU Juan, JIANG Shuli, TENG Changcai. Bioinformatics analysis of miR-301b expression and survival status of patients with ovarian cancer based on TCGA database [J]. Journal of Modern Laboratory Medicine, 2020, 35(4):37-40.
[13] TONG Deyong, ZOU Erwen, BAI Li, et al. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition[J]. Journal of B.U.ON, 2020, 25(5): 2205-2214.
[14] CAO Danxia, ZHU Han, ZHAO Qian, et al. MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells[J]. Biological Research, 2020, 53(1): 43.
[15] 何哲炜，郭文坚．外泌体源性微小 RNA在急性髓细胞白血病中的研究现状 [J]．国际输血及血液学杂志，2020，43(1)：23-24． HE Zhewei, GUO Wenjian. Research status of exosome-derived microRNA in acute myeloid leukemia [J]. International Journal of Blood Transfusion and Hematology, 2020, 43(1):23-26.
[16] LIU Tong, ZHANG Xin, DU Lutao, et al. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer[J]. Molecular Cancer, 2019, 18(1): 43.
[17] ZENG Juan, LI Yukun, QUAN Feifei, et al. Propofol-induced miR-125a-5p inhibits the proliferation and metastasis of ovarian cancer by suppressing LIN28B[J]. Molecular Medicine Reports, 2020, 22(2): 1507-1517.
[18] WANG Junrong, HU Yubo, YE Cong, et al. miR-1224-5p inhibits the proliferation and invasion of ovarian cancer via targeting SND1[J]. Human Cell, 2020, 33(3): 780-789.
[19] ZHANG R R, WANG L M, SHEN J J. Over expression of miR-32 inhibits the proliferation and metastasis of ovarian cancer cells by targeting BTLA[J]. European Review for Medical and Pharmacological Sciences, 2020, 24(9): 4671-4678.
[20] CHEN Xiuhui, MANGALA L S, MOOBERRY L, et al. Identifying and targeting angiogenesis-related microRNAs in ovarian cancer[J]. Oncogene, 2019, 38(33): 6095-6108.
相似文献/References:
[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point
of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(06):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6
in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(06):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and
CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(06):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell
SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(06):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR,
RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(06):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[9]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[10]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(06):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]